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Abstract
Aims We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) com-
pared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia).
We further wanted to determine the incidence of HF events and its consequences in these patient populations.
Methods and results International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with
COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in
28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized
with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62–81] years, 58%
male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital
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mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio
[OR] 1.93 [95% confidence interval: 1.44–2.59], P < 0.001). After adjusting, HF remained associated with in-hospital mortality
(OR 1.45 [95% confidence interval: 1.01–2.06], P = 0.041). Importantly, 186 of 1282 [15%] patients had an acute HF event dur-
ing hospitalization (76 [40%] with de novo HF), which was associated with higher in-hospital mortality (89 [48%] vs. 220 [23%])
than in patients without HF event (OR 3.10 [2.24–4.29], P < 0.001).
Conclusions Hospitalized COVID-19 patients with HF are at increased risk for in-hospital death. In-hospital worsening of HF
or acute HF de novo are common and associated with a further increase in in-hospital mortality.
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Introduction
Coronavirus disease 2019 (COVID-19) became an unprece-
dented global challenge affecting all fields of medicine. Al-
though initially seen as a viral disease affecting primarily
the lungs, it has been hypothesized that other organ systems
are affected as well.1 Systemic hyperinflammation after initial
viral pneumonia and/or direct viral infection play an impor-
tant role in the development of the systemic manifestations
of COVID-19.2 Because the severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV2) infects its host through
angiotensin-converting enzyme (ACE) 2 receptors, which are
also localized on the endothelium, subsequent endothelial
dysfunction and generalized endotheliitis may lead to further
pathophysiological cascade.2 Patients with a history of car-
diovascular (CV) disease, heart failure (HF), and/or CV risk
factors seem to be at higher risk for COVID-19 and an
unfavourable clinical course once infected.3–6 A possible ex-
planation might be the pre-existing endothelial dysfunction.5
Various cardiac manifestations during COVID-19 have been
reported, and biomarkers of cardiac damage are increased
in 5–25% of hospitalized COVID-19 patients.7 Studies have
demonstrated an increased mortality in patients with con-
comitant CV disease. A large retrospective cohort study in
US veterans tested positive for SARS-CoV-2 in the ambulatory
setting reported that patients with COVID-19 and previously
diagnosed HF had a higher risk of hospital admissions and
30 day mortality.8 An impaired prognosis can be expected
in patients requiring hospitalization with COVID-19 diagnosis.
Single-centre and nationwide cohort studies showed that
COVID-19 affected referral and hospitalizations of patients
with acute HF and that HF was associated with high
mortality.9–18 Yet, the impact of COVID-19 on HF patients
and vice versa the relevance of HF events during COVID-19
in a multicentre international cohort is unknown.19,20 There-
fore, the Postgraduate Course in Heart Failure (PCHF) group
built an international multicentre registry for hospitalized
COVID-19 patients with CV diseases and/or risk factors
(CVDRF). The aim of the study was to assess the outcome
of patients with a history of HF compared with patients with-
out a history of HF in this CVDRF population. The second aim




The study was approved by the Ethics Committee of Zurich,
Switzerland (BASEC-Nr. 2020-00853) and registered in the
ClinicalTrials.gov database as The Global PCHF-COVICAV
Registry (PCHF-COVICAV), Identifier NCT04390555. For the
leading investigating centre in Switzerland, informed consent
was given by all patients but waived for patients who died
before consent could be retrieved. Further details on
ethics/informed consent per contributing country are listed
in the supplements.
Study population
This multicentre, international retrospective cohort study
included adult hospitalized patients (≥18 years old) with
laboratory confirmed COVID-19 defined as positive result
by polymerase chain reaction testing of a nasopharyngeal
sample or a positive blood antigen test. Exclusion criteria
for the registry were (i) age less than 18 years at hospital-
ization and (ii) outpatients. The following cohorts were de-
fined (Figure 1).
Cardiovascular disease and/or risk factor cohort
Subjects with pre-existing CV disease and/or cardiac manifes-
tations of COVID-19 (HF, acute coronary syndrome, myocardi-
tis, arrhythmias, pulmonary embolism, and sudden cardiac
arrest) and/or one of the following CV risk factors: arterial hy-
pertension, diabetes, or dyslipidaemia, were extensively
2 M. Sokolski et al.
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13549
characterized as the main population for the study. We de-
fined two subgroups:
i HF subgroup: patients with a history of HF according to the
European Society of Cardiology guidelines, including HF
with preserved ejection fraction (HFpEF), HF with
mid-range ejection fraction (HFmrEF), or HF with reduced
ejection fraction (HFrEF).21
ii Non-HF subgroup: patients with CVDRF, but without a his-
tory of HF.
Inpatients with COVID-19, not meeting CVDRF criteria, served
as a separate control cohort. For these patients, only the fol-
lowing variables were recorded: age, sex, intensive care unit
(ICU) hospitalization (binary yes/no), and in-hospital death.
Dataset
Patients were included from the beginning of the COVID-19
pandemic (early 2020) until data transfer deadline (20th of
May 2020, = first wave). Patients that were still hospitalized
after the data transfer deadline (20th of May 2020) or with-
out available information on the primary endpoint or on HF
status (history of HF) (study primary focus) were excluded
from the data analysis (Supporting Information, Table S1).
Study procedures
The demographic (age, gender, and race), clinical (medical
history, current medication at admission, cardiac manifesta-
tions of COVID-19 at admission, signs and symptoms at ad-
mission, and physical examination at admission), laboratory,
chest X-ray and/or computed tomography, electrocardiogra-
phy, echocardiography, in-hospital clinical course, and com-
plications of COVID-19 data were extracted from electronic
medical records using a standardized data collection form.
Definitions of measured variables, calculated variables, and
causes of death categories are shown in Supporting
Figure 1 Flow chart with inclusion and exclusion of patients in the multicentre registry. *Patients with a history of cardiovascular disease, cardiovas-
cular manifestation during hospitalization for COVID-19, arterial hypertension, diabetes, or dyslipidaemia. **Patients with an HF event at admission or
during hospitalization for COVID-19. CV, cardiovascular; CVDRF, cardiovascular disease and/or risk factors; HF, heart failure; PCHF-COVICAV, Postgrad-
uate Course for Heart Failure registry for COronaVirus-19 patients with CArdioVascular disease and/or risk factors.
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Information, Methods and Supporting Information, Table S2.
More than one cause of death could be entered by the
researchers.
Data pooling and standardization
Data were collected from 28 university or large regional cen-
tres in 15 countries. All investigators were affiliated with the
PCHF, an international advanced HF training programme initi-
ated by the Heart Failure Association of the European Society
of Cardiology, the European Heart Academy, and the Univer-
sity of Zurich. Patient inclusion was limited by COVID-19 rate
and local regulations to COVID-19 triage. Whenever centres
provided a selection of eligible patients, we tried to obtain
consecutive patients.
Data cleaning, quality check, and validation
Definitions of clinical manifestations may vary between coun-
tries and centres. We developed a standardized data collec-
tion form, accompanied by a dictionary, which were used
by all participating centres to reduce heterogeneity
(Supporting Information, Table S2). The pseudonymized
forms (secured keys are stored by the local centres) were col-
lected by the core working group, merged into one general
database, and a general identifier per patient was created.
Data quality of all variables was checked. For categorical
variables, numbers not identifying any of the predefined cat-
egories were excluded. For continuous variables, time vari-
ables (expressed in number of days): negative values
(<0 days) and values > 365 days, were excluded. For labora-
tory data, units were recalculated to the units presented in
the manuscript for centres where other lab units are used.
Data quality for continuous values was further checked by
systematic evaluation of mean, median, minimum, maximum,
and range of values for every centre and compared with the
overall values. We identified outliers and implausible values,
and if necessary, we queried contributors to resolve any is-
sues encountered.
Laboratory measurements
The following laboratory parameters were collected:
haemoglobin, leukocytes (lymphocytes and neutrophils),
platelets, plasma N-terminal pro-B-type natriuretic peptide
(NT-proBNP), high-sensitivity cardiac troponin T or I,
C-reactive protein (CRP), procalcitonin, arterial blood gases
(pCO2, lactate), aspartate aminotransferase (AST), alanine
aminotransferase (ALT), albumin, creatinine for calculation
of eGFR, serum sodium and potassium, D-dimers, and inter-
national normalized ratio (INR).
Endpoints
The primary endpoint was in-hospital death. Because the
mortality rates due to COVID-19 are known to vary across
countries,22 the individual data points per country are shown
in Supporting Information, Table S3. The secondary endpoints
were intensive care hospitalization and length of stay, the du-
ration of hospitalization, and the need for and duration of
non-invasive mechanical ventilation.
Statistical analysis
Categorical variables are presented as n (%). Continuous var-
iables are described by medians with lower and upper quar-
tiles. Available data are shown in Tables 1 and 2 as n (%)
for all variables. The intergroup differences were tested using
Student’s t-test for normally distributed data and the Mann–
Whitney U test for non-normally distributed data. Propor-
tions were compared using χ2 test or Fisher’s exact test,
where appropriate. The associations between clinical vari-
ables and an HF event and between clinical and laboratory
variables and in-hospital mortality were tested using logistic
regression models.
To estimate the effect of HF and HF events on in-hospital
mortality, Kaplan–Meier curves with time to in-hospital death
were constructed (Figure 2A,B). Time to event was calculated
from date of hospital admission to in-hospital all-cause death.
Patients were censored at time of hospital discharge and end
of follow-up time (30 days after initial hospital admission).
Confounders for multivariable regression were identified
based on clinical knowledge and published literature. For
the logistic regression analysis in Figure 2C,D, multivariable
analysis was sequentially adjusted for age, sex, risk factors
(arterial hypertension, diabetes, dyslipidaemia, and history
of smoking), and co-morbidities [malignancy and chronic kid-
ney disease (CKD) with eGFR < 60 mL/min/1.73 m2] to test
which variables most strongly represent the increased risk as-
sociated with HF. We tested for interaction between history
of HF with sex and age. For Table 3 and Supporting Informa-
tion, Table S9, the multivariable model included variables that
were statistically significant in the univariable models (all rep-
resented in the tables). The following sensitivity analyses
were performed: (i) the baseline characteristics and out-
comes for the analysed cohort in the multivariable model of
Table 3 and the cohort with missing data are shown in
Supporting Information, Table S4, (ii) exclusion of Italy as
the largest contributing country to the registry (Supporting
Information, Results), and (iii) comparison of baseline charac-
teristics and in-hospital course of the five largest contributing
countries to the registry (Supporting Information, Table S5).
All analyses were performed using SPSS (IBM, Version 26)
and STATISTICA 13.3 (StatSoft, Inc), and P values < 0.05 were
considered statistically significant.
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Table 1 Baseline clinical characteristics
Variables, units
CVDRF, overall HF subgroup Non-HF subgroup
n = 1282 n = 256 n = 1026
Demographic parameters
Age, years 72 [62–81] (1281) 76 [68–84]** (256) 71 [61–80] (1025)
Sex, male 746/1282 (58) 145/256 (57) 601 (59) (1026)
Race, Caucasian 962/1101 (84) 219/234 (94)* 743/867 (86)
Body mass index, kg/m2 27 [24–31] (907) 28 [24–32] (213) 27 [24–31] (694)
Cardiovascular risk factors
Arterial hypertension 986/1277 (77) 214/254 (84)* 772/1023 (75)
Dyslipidaemia 563/1275 (44) 153/255 (60)** 410/1020 (40)
Diabetes mellitus 434/1279 (34) 112/256 (44)** 316/1023 (31)
Previous/current smoker 375/1218 (31) 96/244 (39)* 279/974 (29)
Family history of heart disease 123/1024 (12) 63/225 (28)** 60/799 (8)
Cardiovascular diseases
Ischaemic heart disease 306/1226 (24) 154/249 (62)** 152/977 (16)
Prior ACS 163/1100 (15) 89/232 (38)** 74/868 (9)
Atrial fibrillation 233/1242 (19) 100/255 (39)** 133/987 (13)
Significant valvular heart disease 115/1231 (9) 63/250 (25)** 52/981 (5)
Stroke/transient ischaemic attack 132/1113 (12) 50/238 (21)** 82/875 (9)
Peripheral artery disease 125/1242 (10) 45/254 (18)** 80/988 (8)
Other co-morbidities
Chronic kidney diseasea 185/1233 (15) 73/250 (29)** 112/983 (11)
COPD or asthma 185/1110 (15) 63/238 (26)** 124/872 (14)
Malignancy 143/1111 (13) 33/238 (14) 110/873 (13)
Treatment before admission
Loop diuretics 307/1227 (25) 160/252 (63)** 147/975 (15)
ACE inhibitors 331/1101 (30) 105/235 (45)** 226/866 (26)
ARB 251/1103 (23) 50/236 (21) 201/867 (23)
Beta-blockers 457/1234 (37) 171/253 (68)** 286/981 (29)
Calcium channel blockers 335/1230 (27) 67/253 (26) 268/977 (27)
MRA 97/1231 (8) 66/253 (26)** 31/978 (3)
Oral antidiabetics incl. SGLT2i 260/1236 (21) 60/237 (24) 200/981 (20)
Insulin 154/1236 (12) 46/254 (18) 108/982 (11)
Statin 466/1234 (38) 130/253 (51)** 336/981 (34)
Antiplatelet treatment 392/1233 (32) 133/252 (53)** 259/980 (26)
Oral anticoagulants 186/1236 (15) 80/252 (32)** 106/983 (11)
NSAIDS 47/1234 (4) 11/253 (4) 36/981 (4)
Pacemaker 62/1241 (5) 27/255 (11)** 35/986 (4)
ICD/CRT 15/1111 (1) 14/238 (6)** 1/873 (0)
Signs and symptoms at admission
Fever 783/1077 (73) 160/238 (67)* 623/839 (74)
Cough 655/1069 (61) 151/235 (64) 504/834 (60)
Dyspnoea 692/1073 (64) 193/238 (81)** 499/835 (60)
Orthopnoea 100/1072 (9) 57/236 (24)** 43/836 (5)
Chest pain 100/1078 (9) 29/239 (12) 71/839 (8)
Tiredness/fatigue 361/1073 (34) 102/238 (43)** 259/835 (31)
Runny nose 58/1076 (5) 18/237 (8) 40/839 (5)
Sore throat 74/1076 (7) 27/237 (11)* 47/839 (6)
Gastrointestinal symptoms 193/1077 (18) 33/238 (14) 160/839 (19)
Myalgia 177/1075 (16) 54/237 (23)* 123/838 (15)
Altered smell or taste 79/1064 (7) 25/231 (11)* 54/833 (6)
Body temperature, °C 37.5 [36.7–38.1] (1125) 37.8 [37.0–38.2]* (228)* 37.4 [36.6–38.1] (897)
Respiratory rate, /min 20 [17–25] (794) 21 [18–24] (178) 20 [16–25] (616)
Heart rate, b.p.m. 85 [75–99] (1156) 85 [75–100] (96) 85 [76–98] (910)
Systolic blood pressure, mmHg 130 [120–144] (1166) 130 [111–140]** (248) 130 [120–145] (918)
Diastolic blood pressure, mmHg 76 [67–84] (1163) 75 [62–82]* (247) 77 [68–84] (916)
Oxygen saturation 94 [90–96] (1118) 93 [89–96]** (233) 94 [90–96] (885)
Peripheral oedema 106/1052 (10) 70/231 (30)** 36/821 (4)
Chest X-ray
Inflammatory changes 731/894 (82) 173/204 (85) 558/690 (81)
Signs of congestion 250/885 (28) 98/199 (49)** 152/686 (22)
Pleural effusion 159/888 (18) 56/203 (28)** 103/685 (15)
Computed tomography
Subpleural ground glass 305/425 (72) 75/109 (69) 230/316 (73)
Consolidations 157/425 (37) 36/109 (33) 121/316 (38)
(Continues)
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CVDRF, overall HF subgroup Non-HF subgroup
n = 1282 n = 256 n = 1026
Laboratory parameters
Haemoglobin, g/L 128 [114–141] (1138) 120 [106–135]** (246) 130 [117–142] (892)
White blood cells, × 109/L 6.8 [5.0–9.7] (1201) 7.5 [5.3–10.6]* (253) 6.5 [4.9–9.5] (948)
Lymphocytes, % 15 [10–22] (1132) 13 [7–20]** (231) 15 [10–23] (901)
Neutrophils, % 76 [67–83] (1129) 79 [71–85]* (229) 76 [67–83] (900)
Blood platelets, 109/L 196 [154–262] (1019) 177 [141–256]* (207) 199 [157–262] (812)
NT-proBNP, ng/L 733 [226–2352] (408) 2352 [885–6630]** (100) 506 [149–1572] (308)
hs-troponin T or I, × ULN 0.9 [0.3–3.5] (500) 1.1 [0.4–5.7] (113) 0.9 [0.3–2.9] (387)
C-reactive protein, mg/L 63 [26–130] (1155) 58 [31–130] (236) 64 [25–130] (919)
Procalcitonine, ng/mL 0.2 [0.1–0.4] (589) 0.2 [0.1–0.6]** (93) 0.1 [0.1–0.3] (496)
pCO2, kPa (arterial blood gas) 4.6 [4.1–5.1] (754) 4.6 [4.0–5.3] (151) 4.5 [4.1–5.1] (603)
Lactate, mmol/L 1.2 [0.9–1.9] (667) 1.6 [1.0–2.0]** (138) 1.2 [0.9–1.8] (529)
Albumin, g/L 34 [30–38] (613) 33 [28–37]* (133) 35 [30–38] (480)
ALT, U/L 28 [18–44] (1133) 24 [16–42]* (236) 29 [19–45] (897)
AST, U/L 35 [24–56] (828) 33 [21–63] (203) 36 [24–54] (625)
Creatinine, mg/dL 1.0 [0.8–1.4] (1075) 1.3 [1.0–1.9]** (233) 1.0 [0.8–1.3] (842)
GFR, mL/min/1.73 m2 64 [43–86] (1074) 49 [34–71] (233) 67 [47–89] (841)
Potassium, mmol/L 4.0 [3.7–4.4] (1173) 4.2 [3.7–4.6]** (254) 4.0 [3.7–4.4] (919)
Sodium, mmol/L 138 [135–141] (1194) 139 [136–141]* (256) 138 [135–140] (938)
INR 1.1 [1.0–1.2] (824) 1.2 [1.1–1.5]** (275) 1.1 [1.0–1.2] (649)
D-dimers, μg/mL 1.0 [0.6–1.9] (568) 1.1 [0.5–1.9] (125) 1.0 [0.6–1.9] (443)
ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; ALT, alanine transaminase; ARB, angiotensin receptor blocker; AST,
aspartate transaminase; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CVDRF, patient cohort
with cardiovascular disease and/or risk factors; HF, heart failure; ICD, internal cardiac defibrillator; INR, international normalized ratio;
MRA, mineralocorticoid receptor antagonists; NSAID, non-steroidal inflammatory drugs; NT-proBNP, N-terminal pro-type brain natriuretic
peptide; SGLT2i, sodium-glucose transporter inhibitors.
Results are presented as an n patients/available n (with percentage) or as a median [lower and upper quantile] (available n).
*P < 0.05.
**P < 0.001.
aChronic kidney disease: eGFR < 60 mL/min/1.73 m2.
Table 2 In-hospital events
Variables
CVDRF, overall HF subgroup Non-HF subgroup
n = 1282 n = 256 n = 1026
Cardiac manifestations during hospitalization
Heart failure event 186/1150 (16) 110/240 (46)** 76/910 (8)
Acute coronary syndrome 39/1150 (3) 13/240 (5) 26/910 (3)
Myocarditis 12/1149 (1) 5/240 (2) 7/909 (1)
Ventricular arrhythmias 18/1137 (2) 8/238 (3)* 10/899 (1)
Pulmonary embolism 33/1122 (3) 9/229 (4) 24/893 (3)
Other thromboembolic events 25/1135 (2) 8/237 (3) 17/898 (2)
In-hospital course and outcome
Mechanical ventilation 211/1202 (18) 54/253 (21) 157/949 (17)
Non-invasive ventilation 358/1066 (34) 111/233 (48)** 247/833 (30)
Respiratory failure 650/1267 (51) 160/254 (63)** 490/1013 (48)
Sepsis 191/1133 (17) 43/236 (18) 148/897 (16)
Septic shock 109/1132 (10) 23/235 (10) 86/897 (10)
Multi-organ failure 199/1137 (18) 60/237 (25)** 139/900 (15)
Renal replacement therapy 60/1074 (6) 15/235 (6) 45/839 (5)
ICU 301/1275 (24) 85/254 (33)** 216/1021 (21)
ICU, length of stay, days 4 [0–11] (457) 4 [0–8] (129) 4 [0–14] (32)
Length of hospital stay, days 11 [5–19] (834) 12 [6–19] (143) 11 [5–19] (706)
In-hospital death 323/1282 (25) 92/256 (36)** 231/1026 (23)
CVDRF, patient cohort with cardiovascular disease and/or risk factors; HF, heart failure; ICU, intensive care unit hospitalization.
Results are presented as a number of patients (with percentage) or as a median [with lower and upper quartile].
*P < 0.05.
**P < 0.001.
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Results
Description of the study population
The registry included 2015 hospitalized patients with labora-
tory confirmed COVID-19; 28 patients were excluded due to
ongoing hospitalization or unknown survival status at dis-
charge and 13 due to unknown HF status (see flow chart
Figure 1 and Supporting Information, Table S2). Patients with
CVDRF (n = 1282, 58% male, median age 72 [interquartile
range 62–81] years) were classified into patients with a
history of HF (HF subgroup, n = 256, 20% of CVDRF, 57% male,
32% HFpEF) and patients without a history of HF (non-HF sub-
group, n = 1026, 80% of CVDRF, 59% male) (Table 1). HF
patients were older (76 [68–84] vs. 71 [61–80] years,
P < 0.001) and had more risk factors and co-morbidities than
non-HF patients (Table 1). Patients with HF showed a higher
NT-proBNP than non-HF patients and were further character-
ized by a lower haemoglobin and blood platelets, but higher
white blood cell counts, lactate, liver tests, and creatinine at
the emergency blood sampling. However, high-sensitivity tro-
ponin levels and CRP were not significantly different between
Figure 2 (A) Kaplan–Meier curve showing overall 30 day in-hospital mortality, stratified for patients with a history of heart failure (HF), patients with
cardiovascular disease and/or risk factors without HF (CVDRF, no HF), and patients without CVDRF (control cohort). (B) Thirty-day in-hospital mortality
for patients with CVDRF, stratified for the occurrence of an HF event at admission or during hospitalization for COVID-19. (C, D) Step-wise modelling of
risk of in-hospital mortality in COVID-19 patients with a history of HF (C) or HF events (D), adjusted for age, sex, risk factors (arterial hypertension,
diabetes, hypercholesterolaemia, and smoking), and co-morbidities (malignancy and chronic kidney disease with eGFR < 60 mL/min/1.73m2) (data
available in Supporting Information, Tables S8 and S10). comorb., co-morbidities; HF, heart failure; RF, risk factors.
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HF and non-HF patients (Table 1). A total of 95/1282 (7%) pa-
tients were hospitalized with symptoms of acute HF; the other
patients had mainly COVID-19 symptoms without overt de-
compensation at hospitalization. Of the 220 patients where
ACE inhibitor was discontinued, the date of withdrawal was
recorded in 190 patients. In 97% (185 out of 190), ACE inhib-
itor was withdrawn directly after admission.
Data of COVID-19 hospitalized patients without CV disease,
cardiac manifestation of COVID-19 and/or CV risk factors
(n = 692, age 54 [44–63] years, 55% male), were briefly sum-
marized for survival status at discharge (n = 39/692 in-hospi-
tal deaths, 6%) and intensive care hospitalization (n = 86/692;
12%) (Supporting Information, Table S7).
In-hospital mortality
The CVDRF cohort had high overall in-hospital mortality (25%,
n = 323/1282 deaths). In-hospital mortality was higher in pa-
tients with HF (36%, n = 92) compared with non-HF patients
(23%, n = 231, P < 0.001) with an odds ratio (OR) of 1.93
[95% confidence interval, CI: 1.44–2.59] (Figure 2A,C). After
adjusting for age, sex, risk factors, and co-morbidities, HF
remained associated with in-hospital mortality (OR 1.45
[95% CI: 1.01–2.06], P = 0.041) (Figure 2C and Supporting
Information, Figure S1 and Table S8). Interaction for history
of HF and age was significant (P = 0.029), with an OR for his-
tory of HF and in-hospital death of 2.02 ([95% CI: 1.17–3.49],
P = 0.012) in the <75 years age group and 1.26 [95% CI:
0.80–1.99], P = 0.32) in the ≥75 years age group. There was
no significant interaction between history of HF and sex
(P = 0.42).
Main causes of in-hospital death (available in 250/323
deaths) were respiratory failure/acute respiratory distress
syndrome (n = 127, 51%), multiple organ failure (n = 84,
34%), CV death (n = 34, 14%), and septic shock (n = 35,
14%). CV death was more reported in the HF subgroup
(n = 16/76 (21%) vs. n = 18/174 (10%), P = 0.023) (Supporting
Information, Figure S2A).
Patients with HF more often required intensive care hospi-
talization and non-invasive ventilation (33% vs. 21%, and 48%
vs. 30%, respectively, both P < 0.001); however, length of
stay on intensive care or total hospitalization duration were
not significantly different (Table 2). In a subgroup analysis,
patients with HFrEF more often required ICU hospitalization;
however, we did not see a difference in in-hospital death,
compared with patients with HFpEF (Supporting Information,
Table S11).
In patients with HF, age, valvular heart disease, malignancy,
previous treatment with loop diuretics, the absence of ACE in-
hibitor treatment, higher creatinine, higher CRP, and low lym-
phocyte count were associated with higher in-hospital
mortality. After multivariable adjustment, higher age (OR
1.18 [95% CI: 1.06–1.34], per 5 years), absence of ACE inhibi-
tion (OR 3.75 [95% CI: 1.89–7.44]), and a higher CRP level at
admission (OR 1.73 [95% CI: 1.25–2.37], per 1 Ln mg/L)
Table 3 Predictors of heart failure events in patients with COVID-19 and cardiovascular risk factors/disease
Variables, units
Univariable models Multivariable model
OR (95% CI) P OR (95% CI) P
Demographic parameters
Age, per 5 years 1.20 (1.12–1.28) <0.001 1.08 (0.99–1.17) 0.09
Sex, men 1.29 (0.94–1.77) 0.12 — —
Body mass index, kg/m2 0.99 (0.96–1.03) 0.46 — —
Cardiovascular risk factors
Arterial hypertension 1.79 (1.16–2.76) 0.008 1.29 (0.78–2.13) 0.32
Dyslipidaemia 1.76 (1.28–2.42) <0.001 1.15 (0.77–1.70) 0.49
Diabetes 1.59 (1.16–2.19) 0.004 1.27 (0.87–1.86) 0.22
Smoking 1.06 (0.74–1.51) 0.77 — —
Cardiovascular diseases
History of heart failure 9.29 (6.57–13.12) <0.001 6.21 (3.99–9.68) <0.001
Ischaemic heart disease 2.82 (2.03–3.92) <0.001 1.01 (0.61–1.67) 0.98
Atrial fibrillation 3.79 (2.67–5.39) <0.001 2.10 (1.38–3.20) <0.001
Valvular heart disease 3.41 (2.17–5.36) <0.001 1.15 (0.66–2.01) 0.62
Stroke/TIA 1.67 (1.08–2.58) 0.022 1.08 (0.63–1.85) 0.77
Peripheral artery disease 1.70 (1.07–2.68) 0.024 0.78 (0.44–1.41) 0.41
Other co-morbidities
CKD (eGFR < 60 mL/min/1.73 m2) 2.99 (2.11–4.23) <0.001 1.71 (1.10–2.68) 0.017
COPD or asthma 1.53 (1.03–2.25) 0.034 0.91 (0.56–1.45) 0.68
Malignancy 1.33 (0.85–2.07) 0.21 — —
CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive lung disease; eGFR, estimated glomerular filtration rate;
OR, odds ratio; TIA, transient ischaemic attack.
The multivariable model included variables with a P value < 0.10 in the univariable models. χ2 = 180.5, P < 0.001, included n = 1064/
1282.
The statistically significant OR (95% CI) in the univariable and multivariable models were presented with bold.
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remained significantly associated with in-hospital mortality in
patients with HF (Supporting Information, Table S9).
In-hospital heart failure events
Of all patients in the CVDRF cohort, 186 (15%) patients expe-
rienced HF events at admission or during hospitalization, of
which 110/240 (46%) patients in the HF subgroup and 76/
910 (8%) in the non-HF subgroup, the latter accounting for
40% of all observed HF events (Table 2). In the CVDRF cohort,
patients with an HF event were at a two-fold increased risk
for in-hospital mortality compared with those without HF
events (n = 89 [48%] vs. n = 220 [23%], P < 0.001, OR 3.10
[2.24–4.29]), even after adjustment for age, sex, risk factors,
and co-morbidities (Figure 2B,D and Supporting Information,
Table S10). Interaction for HF events and age was significant
(P = 0.023), with an OR for HF events and in-hospital death of
3.41 (95% CI [1.96–5.93], P ≤ 0.001) in the <75 years age
group and 2.82 (95% CI [1.71–4.65], P < 0.001) in the
≥75 years age group. There was no significant interaction be-
tween HF events and sex (P = 0.58). Age, CV diseases, CV risk
factors, history of HF, atrial fibrillation, and CKD were signifi-
cantly associated with HF events. After multivariable adjust-
ment, CKD (eGFR < 60 mL/min/1.73 m2) (OR 1.71 [1.10–
2.68], P = 0.017), atrial fibrillation (2.10 [1.38–3.20],
P < 0.001), and history of HF (OR 6.21 [3.99–9.68],
P < 0.001) remained independently associated with HF
events in patients hospitalized for COVID-19 (Table 3).
Discussion
In this registry of 1282 patients with CV disease and/or risk
factors hospitalized for COVID-19, we assessed a population
with a high overall in-hospital mortality (25%). Particularly,
patients with a history of HF (256 patients) experienced a
1.5-fold increased likelihood for in-hospital death after ad-
justment for known confounders. Those experiencing an
in-hospital HF event, which occurred in 186 patients (40%
without history of HF), had a three-fold increased adjusted
likelihood for in-hospital death.
Cardiovascular disease and CV risk factors have been in-
creasingly recognized as predisposing determinants of worse
outcomes in COVID-19 since the beginning of the pandemic.
However, the role of HF remains elusive. In this multicentre
registry, we observed a high in-hospital mortality that was par-
ticularly high in patients with pre-existing HF. Although HF pa-
tients in the CVDRF cohort were older and presented with
more CV risk factors and co-morbidities than non-HF patients,
HF remained independently associated with in-hospital mor-
tality, after adjustment for potential confounders. HF preva-
lence in the present registry was 20%, thus corroborating
findings of registries that primarily focused on CV risk factors,
such as diabetes and hypertension, or ischaemic heart disease,
reporting an HF prevalence between 4.1% and 23%.20,23–25
These observations also apply to ambulatory patients with
COVID-19. Among 31 051 patients with COVID-19, 6148
(20%) had pre-existing HF and those have a 30 day mortality
and 30 day admission rate of 5.4% and 18.5%, respectively.8
In contrast, in our study, we only observed patients already
hospitalized. There, HF was present in 29% of all patients
who died while hospitalized compared with 17% in survivors,
suggesting HF as a potential contributor to COVID-19 in-hospi-
tal mortality. Findings from other studies reinforce this hy-
pothesis, by showing that non-survivors were more likely to
have a history of HF (52%) than survivors (12%).20 Yet another
study reported a very high prevalence of HF (49%) in deceased
patients (n = 113).26 Further, a recent single-centre registry in-
cluded 152 (4.9%) HF patients with a similarly high mortality
among patients with chronic HF (48.7%). In contrast to our
study, HF was not independently associated with mortality.11
The HF patients of this study were older (82 ± 12 years old)
compared with the HF population in our registry. In our regis-
try, a subgroup analysis for a younger or older age than
75 years showed heterogeneity for the primary outcome.
However, there was a consistent association of HF and
in-hospital death in the overall CVDRF cohort. In contrast to
the multicentre French registry, we did not observe a differ-
ence in in-hospital mortality between HFpEF and HFrEF pa-
tients—however, the latter more often required ICU
hospitalization (Supporting Information, Table S11).27
Interestingly, not only patients with pre-existing HF seem to
be at risk for developing an HF event when infected with
COVID-19, but also a substantial number of patients with CV
risk factors without previously known HF. Further, not only a
history of HF but particularly HF events when hospitalized for
COVID-19 were associated with an excess mortality, thus
supporting and extending findings from a single-centre regis-
try from Madrid demonstrating that HF events were associ-
ated with a high mortality.11 Several risk factors could
potentially contribute to these HF events, triggered by
COVID-19.
Nevertheless, the pathophysiology of COVID-19 and risk
of HF still remains incompletely understood. Imaging studies
have shown myocardial inflammation, frequently persisting
after recovery from COVID-19.28,29 In addition, in a system-
atic echocardiographic evaluation in 100 COVID-19 patients,
both right ventricular and left ventricular diastolic and sys-
tolic dysfunction were found in 39% and 26% of patients.30
Of note, 40% of the HF events were de novo. One mecha-
nism might be direct infection with SARS-CoV-2 of myocar-
dial tissue, through the ACE 2 receptor.7 However, careful
analysis of pathology specimens of deceased COVID-19 pa-
tients revealed viral inclusion structures in endothelial cells,
and in addition, an accumulation of inflammatory cells asso-
ciated with the endothelium in other organs than the lung,
such as heart and kidney, suggestive of an overwhelming
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inflammatory response.2 The findings in our HF cohort
strengthen this hypothesis, as patients with high CRP as a
surrogate for a more severe inflammatory response had a
worse outcome. Further, HF is characterized by profound en-
dothelial dysfunction, particularly in advanced ischaemic
heart disease.5,31,32 Ischaemic heart disease was prevalent
in 64% of the HF group.
We recognized a high number of ACE inhibitor and angio-
tensin receptor blocker withdrawal in our cohort. This may
have been influenced by the discussion on these medications
at the beginning of the pandemic. Subsequent studies clearly
demonstrate that renin–angiotensin–aldosterone system in-
hibitors should be continued in hospitalized COVID-19 pa-
tients if there is an indication for treatment.33,34
Thromboembolic events are of major concern in COVID-19
patients. We observed pulmonary embolism and other
thrombotic events in 33 out of 1122 (3%) and in 25 out of
1135 patients (2%), respectively. As other studies reported
higher prevalence of such events, we suppose that in our
study thromboembolic events are underestimated.35,36 How-
ever, due to the high risk profile of our study population,
anticoagulation or platelet antiaggregation treatment was
used in most of the study patients prior to and/or during hos-
pitalization (1046/1214 [82%]).
Taken together, HF may be recognized as the end of a
spectrum of CV risk factors, with more advanced pre-existing
endothelial dysfunction and thereby associated with a higher
risk for an overwhelming inflammatory response to
COVID-19. Our results thereby reinforce the importance of
HF as a significant risk factor for death in hospitalized
patients. As important questions about the pathophysiology,
treatment and prognosis of HF patients with COVID-19 re-
main unanswered; prospective outcome studies in
COVID-19 patients with HF are needed.
Limitations
This registry was established within the PCHF network with
investigators dedicated to HF care. Although all patients
who were consecutively admitted to the hospitals are in-
cluded into the registry, a certain selection bias cannot be ex-
cluded. We are further aware that our study may have the
limitations of multicentre registries, both having limited op-
portunities for data verification of each patient and the disad-
vantages of the retrospective observational nature of our
analysis, with its inherent potential selection bias and missing
data. Lastly, mortality rates due to COVID-19 are known to
vary across countries; we added a Supporting Information,
Table S3 showing the detailed in-hospital death per country.
Our findings should therefore be confirmed in prospective
outcome trials.
Conclusions
In this multinational multicentre registry, we demonstrate a
higher mortality for hospitalized COVID-19 patients with HF
compared with patients without HF, even after adjustment
for other conditions and co-morbidities. Particularly, patients
experiencing an HF event during hospitalization for COVID-19
are at high risk for death, an important proportion of whom
did not have a history of HF. The cause of death in most cases
was not related to respiratory failure alone but rather to
multi-organ failure.
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Figure S1. Univariable regression models for demographical
parameters, cardiovascular risk factors, cardiovascular dis-
eases and comorbidities and their association with
in-hospital mortality in patients with CVDRF. BMI = body
mass index, CKD = chronic kidney disease, COPD = chronic ob-
structive pulmonary disease, eGFR = estimated glomerular fil-
tration rate, PAD = peripheral artery disease.
Figure S2. Reported causes of death in patients with cardio-
vascular disease and/or risk factors during hospitalization
for COVID-19 (available in 253/323 deceased patients) in sev-
eral subgroups: (A): total CVDRF group (cardiovascular dis-
ease and/or risk factors), further subdivided in patients with
or without history of heart failure and (B) patients from the
CVDRF group with a heart failure event at admission/during
COVID-19 hospitalization (more than 1 cause of death could
be reported per patient). CVDRF = cardiovascular disease
and/or risk factors; HF = heart failure.
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Figure S3. Age distribution in patients with cardiovascular dis-
ease/and or risk factors (CVDRF cohort).
Table S1. Excluded patients (n) from the registry for the pri-
mary endpoint: regression analysis for in-hospital death in pa-
tients with CVDRF with HF versus patients with CVDRF without
HF. CVDRF: cardiovascular disease and/or risk factors.
Table S2. Data collection sheet.
Table S3. In-hospital death per country.
Table S4. Sensitivity analysis.
Table S5. Baseline characteristics, in-hospital course and out-
come for the 5 largest contributing countries to the registry
(CVDRF group: cardiovascular disease and/or risk factors).
Table S6. Distribution of patients per country (alphabetical or-
der).
Table S7. Demographics and endpoints in the total group and
the sugbroups with or without Cardiovascular Disease/Risk
Factors.
Table S8. Risk of in-hospital death in COVID-19 patients with a
history of heart failure.
Table S9. Predictors of in-hospital death in patients with his-
tory of HF and COVID-19.
Table S10. Risk of in-hospital death in COVID-19 patients
experiencing heart failure events.
Table S11. The comparison of patients with HFpEF vs
HFrEF.
Table S12. The comparison of patients with ADHF vs AHF
de novo.
Table S13. Treatment of acute heart failure in hospitalized
COVID-19 patients.
Table S14. Number and percentage of patients with
multi-organ failure (MOF) and these requiring vasopressors
or inotropic support.
Table S15. Total number of admission mortality in relation
to the magnitude of COVID-19 cases per country.
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